Stuart M. Sprague

Prof. Stuart M. Sprague

Division of Nephrology and Hypertension, NorthShore University Health System, Evanston, IL 60201, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2003 in Kidney International
Verified
Journal Article
Closed access
Stuart M. SpragueStuart M. Sprague
Stuart M. Sprague
FLFrancisco Llach
Francisco Llach
MAMichael Amdahl
Michael Amdahl
CTCarol Taccetta
Carol Taccetta
DBDaniel Batlle
Daniel Batlle

28 September 2016 in American Journal of Nephrology
Verified
Journal Article
Closed access
PDF file
Stuart M. SpragueStuart M. Sprague
Stuart M. Sprague
PCPaul W. Crawford
Paul W. Crawford
JMJoel Z. Melnick
Joel Z. Melnick
SSStephen A. Strugnell
Stephen A. Strugnell
SAShaukat Ali
Shaukat Ali
CBCharles W. Bishop
Charles W. Bishop
Background/Aims: Vitamin D insufficiency and secondary hyperparathyroidism (SHPT) are associated with increased morbidity and mortality in chronic kidney disease (CKD) and are poorly addressed by current treatments. The present clinical studies evaluated extended-release (ER) calcifediol, a novel vitamin D prohormone repletion therapy designed to gradually correct low serum total 25-hydroxyvitamin D, improve SHPT control and minimize the induction of CYP24A1 and FGF23. Methods: Two identical multicenter, randomized, double-blind, placebo-controlled studies enrolled subjects from 89 US sites. A total of 429 subjects, balanced between studies, with stage 3 or 4 CKD, SHPT and vitamin D insufficiency were randomized 2:1 to receive oral ER calcifediol (30 or 60 µg) or placebo once daily at bedtime for 26 weeks. Most subjects (354 or 83%) completed dosing, and 298 (69%) entered a subsequent open-label extension study wherein ER calcifediol was administered without interruption for another 26 weeks. Results: ER calcifediol normalized serum total 25-hydroxyvitamin D concentrations (>30 ng/ml) in >95% of per-protocol subjects and reduced plasma intact parathyroid hormone (iPTH) by at least 10% in 72%. The proportion of subjects receiving ER calcifediol who achieved iPTH reductions of ≥30% increased progressively with treatment duration, reaching 22, 40 and 50% at 12, 26 and 52 weeks, respectively. iPTH lowering with ER calcifediol was independent of CKD stage and significantly greater than with placebo. ER calcifediol had inconsequential impact on serum calcium, phosphorus, FGF23 and adverse events. Conclusion: Oral ER calcifediol is safe and effective in treating SHPT and vitamin D insufficiency in CKD.

13 May 2019 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
JIJoachim H. Ix
Joachim H. Ix
TITamara Isakova
Tamara Isakova
BLBrett Larive
Brett Larive
KRKalani L. Raphael
Kalani L. Raphael
DRDominic S. Raj
Dominic S. Raj
MWMyles Wolf
Myles Wolf
Significance Statement: Higher serum phosphate and fibroblast growth factor-23 (FGF23) levels are potential modifiable risk factors to prevent cardiovascular disease in CKD. Studies evaluating intestinal phosphate binders found modest efficacy for lowering phosphate and FGF23 levels during short-term follow-up in CKD. In their randomized, placebo-controlled trial in 205 participants with stage 3b/4 CKD, the authors evaluated the effects of nicotinamide (an inhibitor of active intestinal phosphate transport), the phosphate binder lanthanum carbonate, or both, versus placebo over 12 months. They found that neither drug, alone or together, reduced serum phosphate or FGF23. Participants taking lanthanum carbonate had reductions in urinary phosphate, however gastrointestinal symptoms limited adherence. Secondary on-treatment analyses suggest that blocking intestinal phosphate absorption may lower FGF23, suggesting potential opportunities for future studies using novel therapies with better tolerability. Background: Higher serum phosphate and fibroblast growth factor-23 (FGF23) levels may be modifiable to prevent cardiovascular disease in CKD. Short-term studies have reported modest efficacy in phosphate and FGF23 reduction with intestinal phosphate binders in CKD. Methods: To investigate effects of lanthanum carbonate (LC; a phosphate binder) and/or nicotinamide (NAM; an inhibitor of active intestinal phosphate transport) on serum phosphate and FGF23 in stage 3b/4 CKD, we conducted a randomized trial among individuals with eGFR 20–45 ml/min per 1.73 m2 to NAM (750 mg twice daily) plus LC (1000 mg thrice daily), NAM plus LC placebo, LC plus NAM placebo, or double placebo for 12 months. Dual primary end points were change from baseline in serum phosphate and intact FGF23 concentrations. Results: Mean eGFR for the 205 participants was 32ml/min per 1.73 m2. At baseline, serum phosphate was 3.7 mg/dl and median FGF23 was 99 pg/ml (10th, 90th percentiles: 59, 205). Mean rates of change in phosphate increased slightly over 12 months in all groups and did not differ significantly across arms. Similarly, percent changes in FGF23 per 12 months increased for all arms except LC plus placebo, and did not differ significantly across arms. Gastrointestinal symptoms limited adherence. Adverse events rates were similar across arms. Conclusions: LC and/or NAM treatment did not significantly lower serum phosphate or FGF23 in stage 3b/4 CKD over 12 months. Although these agents appeared safe, intestinal symptoms limited adherence. Reducing phosphate and FGF23 in nondialysis CKD will require new approaches.

1 January 2009 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
Stuart M. SpragueStuart M. Sprague
Stuart M. Sprague
HAHanna Abboud
Hanna Abboud
PQPing Qiu
Ping Qiu
MDMatthew Dauphin
Matthew Dauphin
PZPinggao Zhang
Pinggao Zhang
WFWilliam Finn
William Finn
Background and objectives: Lanthanum carbonate (FOSRENOL®, Shire Pharmaceuticals) is an effective noncalcium, nonresin phosphate binder for the control of hyperphosphatemia in chronic kidney disease (CKD) stage 5 patients undergoing dialysis. Design, setting, participants and measurements: A Phase 2, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of lanthanum carbonate in CKD stage 3 and 4 patients. Of 281 patients screened, 121 were randomized (2:1) to lanthanum carbonate or placebo (80 versus 41). The modified intent-to-treat population included 90 patients (56 versus 34); 71 (43 versus 28) completed the study. After run-in, when any current phosphate binders were discontinued and dietary counseling reinforced, patients with serum phosphorus >4.6 mg/dl received lanthanum carbonate (titrated up to 3000 mg/d) or matching placebo for 8 wk. Results: At the end of treatment, 25 (44.6%) versus nine (26.5%) patients had serum phosphorus ≤4.6 mg/dl (difference 18.1%, P = 0.12) in the lanthanum carbonate and placebo groups, respectively. Statistically significant differences were observed between groups in change from baseline to end of treatment for serum phosphorus (P = 0.02), intact parathyroid hormone (P = 0.02), and urinary phosphorus excretion (P = 0.04). The safety profile and tolerability of lanthanum carbonate were similar to that of placebo. Conclusions: Because <1% of phosphorus is in the extracellular fluid, serum measurements may not accurately reflect total body burden in patients with CKD stages 3 and 4. However, lanthanum carbonate is an effective phosphate binder in this patient population, with a safety profile and tolerability similar to that of placebo.

1 November 2001 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
Stuart M. SpragueStuart M. Sprague
Stuart M. Sprague
Edgar LermaEdgar Lerma
Edgar Lerma
DMDaniel McCormmick
Daniel McCormmick
MAMohan Abraham
Mohan Abraham
DBDaniel Batlle
Daniel Batlle

1 January 2007 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
Stuart M. SpragueStuart M. Sprague
Stuart M. Sprague
Background: Obstacles to successful management of hyperphosphatemia in chronic kidney disease include inadequate control of dietary phosphate and non-compliance with phosphate-binder therapy. Three major classes of phosphate binders include calcium-based binders, sevelamer HCl, and lanthanum carbonate.Scope: A literature search was performed using MEDLINE and EMBASE databases to identify clinical trials from January 1966 to May 2007 comparing classes of phosphate binders with regard to efficacy, safety, compliance, or pharmacoeconomics. Search terms included lanthanum AND sevelamer, lanthanum AND calcium, and sevelamer AND calcium. A total of 1372 articles were identified in the search, with 125 review articles and clinical trials of interest identified.Findings: Calcium-based binders are effective, but their potential to contribute to total body calcium overload and vascular calcification is an important long-term clinical concern. Sevelamer HCl is effective in reducing serum phosphate, has no sy...